Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A.
Metcalfe
S
S
Department of Surgery, University of Cambridge, Addenbrookes Hospital, England.
Milner
J
J
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D004988:Ethers, Cyclic / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D019319:Okadaic Acid; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010766:Phosphorylation; D011090:Polyenes / Q000494:pharmacology*; D020123:Sirolimus; D013601:T-Lymphocytes / Q000187:drug effects*; D016559:Tacrolimus; D013997:Time Factors
D000900:Anti-Bacterial Agents; D004988:Ethers, Cyclic; D007166:Immunosuppressive Agents; D011090:Polyenes; D019319:Okadaic Acid; D004247:DNA; D010749:Phosphoprotein Phosphatases; D020123:Sirolimus; D016559:Tacrolimus